亚太药业(002370) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥76,231,043.79, a decrease of 10.21% compared to the same period last year[4] - The net profit attributable to shareholders was -¥7,981,457.60, an increase of 10.67% year-on-year, while the net profit after deducting non-recurring gains and losses was -¥7,723,092.55, a decrease of 47.69%[4] - The total operating revenue for the current period is CNY 228,305,775.20, a decrease of 25.6% compared to CNY 306,835,789.08 in the previous period[20] - The operating profit for the current period is CNY 97,259,904.67, compared to a loss of CNY 3,202,585.73 in the previous period, indicating a significant turnaround[21] - The net profit for the current period is CNY 97,195,012.22, a recovery from a net loss of CNY 3,459,530.47 in the previous period[21] - The total comprehensive income attributable to the parent company is ¥97,195,012.22, showing a significant recovery from a loss of ¥2,861,149.28 in the prior period[22] - Basic and diluted earnings per share are both ¥0.1313, an improvement from a loss of ¥0.0056 per share in the previous period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,213,947,013.65, down 13.40% from the end of the previous year[4] - The company's total assets as of September 30, 2025, are CNY 1,213,947,013.65, down from CNY 1,401,768,368.44 at the beginning of the period, representing a decrease of 13.4%[18] - The total liabilities decreased to CNY 92,772,945.76 from CNY 429,587,364.82, a reduction of 78.4%[18] - The company's cash and cash equivalents decreased to CNY 587,809,931.97 from CNY 743,850,694.68, a decline of 21.0%[17] - The inventory level decreased to CNY 52,774,054.96 from CNY 70,128,529.14, reflecting a reduction of 24.8%[17] Cash Flow - The cash flow from operating activities was ¥23,548,958.18, a decrease of 34.35% compared to the same period last year, mainly due to reduced sales receipts[10] - Cash flow from operating activities generated a net cash inflow of ¥23,548,958.18, down from ¥35,870,275.86 in the previous period[24] - Cash inflow from investment activities totaled ¥209,132,163.04, a substantial increase from ¥2,026,063.67 in the prior period[24] - The net cash flow from investment activities is ¥144,780,598.41, recovering from a net outflow of ¥5,107,308.62 in the previous period[24] - Cash and cash equivalents at the end of the period decreased to ¥573,431,601.51 from ¥689,103,730.30 in the previous period[25] - The company repaid debts amounting to ¥277,225,300.00 during the financing activities, compared to ¥50,000,000.00 in the previous period[24] - The total cash outflow from financing activities was ¥314,596,678.34, significantly higher than ¥61,901,761.80 in the prior period[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 91,465[12] - The largest shareholder, Ningbo Fubon Holdings Group, holds 11.99% of shares, totaling 89,420,000 shares[12] - A share transfer agreement was signed on October 13, 2025, involving the transfer of 14.61% of shares (108,945,566 shares) at a price of 8.26 CNY per share, totaling 900 million CNY[13] - After the share transfer, the controlling shareholder will change from Fubon Group to Xinghao Holdings[13] - The company plans to issue A-shares to specific investors, including Zhejiang Xinghao Holdings, pending approval from the shareholders' meeting and regulatory bodies[14] - The share transfer will result in a change of actual control from a management team to Qiu Zhongxun[13] - The top ten shareholders hold a significant portion of shares, with the top two alone accounting for 14.61%[12] - The company has not disclosed any changes in the status of preferred shareholders or their holdings[12] Regulatory and Risk Factors - The share transfer and issuance are subject to regulatory approval, which introduces uncertainty[14] - Investors are advised to analyze the situation carefully due to potential risks associated with the changes in control and share issuance[13] Other Income and Expenses - The company reported a significant increase in investment income of ¥150,238,252.18, up 847.65% year-on-year, primarily due to the sale of its subsidiary[9] - The company’s financial expenses increased by 69.97% to ¥27,893,904.81, mainly due to interest payments on convertible bonds[9] - The company reported a significant increase in other income of ¥5,509,405.28, up 118.12% year-on-year, primarily due to increased government subsidies[9] - The weighted average return on net assets was -0.71%, a decrease of 0.71% year-on-year[4] - The company’s basic and diluted earnings per share were both -¥0.0107, an increase of 25.17% compared to the same period last year[4] Organizational Changes - The company has completed the registration procedures for the change of its subsidiary structure, transitioning from a secondary to a primary subsidiary[15] - The company plans to optimize its organizational structure and improve operational efficiency through the proposed subsidiary changes[15]